# Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy

> **NCT07675668** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Amckaus PTY LTD.** · enrollment: 56 (estimated)

## Conditions studied

- Hypertrophic Cardiomyopathy (HCM)
- Obstructive HCM (oHCM)
- Non-obstructive HCM (nHCM)

## Interventions

- **DRUG:** QG101-23-0 enteric coated capsule (60/120/240/360 mg BID)
- **DRUG:** QG101-23-0 enteric coated capsule (60/120/240/360 mg BID)
- **DRUG:** QG101-23-0 enteric coated capsule (120/240/360/480mg BID)
- **DRUG:** QG101-23-0 enteric coated capsule (60/120/240/360 mg BID)

## Key facts

- **NCT ID:** NCT07675668
- **Lead sponsor:** Amckaus PTY LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675668, "Aom0304 in Adult Patients With Symptomatic Hypertrophic Cardiomyopathy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07675668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*